Introduction
============

Chronic obstructive pulmonary disease (COPD) is a common respiratory condition characterized by progressive airflow obstruction.[@b1-copd-11-697] Exacerbations of COPD, defined as the acute worsening of symptoms, contribute to the overall severity of the disease and can be an important cause of hospital admission and readmission[@b2-copd-11-697] leading to significant disability, decreased quality of life, and an increased risk of death. Additionally, the health care resource use associated with the management of COPD in primary and secondary care results in a substantial economic burden borne by national health care systems.[@b3-copd-11-697]

In the UK, COPD is the most common respiratory condition with an estimated prevalence of 33 cases per 1,000 persons in 2013.[@b4-copd-11-697] We recently showed using UK primary care data that 26.2% of patients with COPD on December 31, 2013 had one exacerbation episode in the year prior to diagnosis, and 25.5% of patients had more than one episode.[@b4-copd-11-697] Risk factors for frequent exacerbations included disease severity measured by stages of airflow obstruction and levels of dyspnea. A retrospective analysis using the same primary care database found COPD management costs to increase with exacerbation frequency and level of dyspnea.[@b3-copd-11-697],[@b5-copd-11-697] General practitioner (GP) interactions were major cost drivers, followed by hospitalizations unrelated to COPD and exacerbations.

In recent years, the assessment of COPD has evolved from defining disease severity as a function of the degree of airflow limitation to the inclusion of patient symptoms, history of exacerbations, and comorbidities.[@b6-copd-11-697] The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 strategy[@b7-copd-11-697] recognizes the importance of a combined assessment of symptom severity and risk of future events determined by exacerbation history, such as recurrent exacerbations, hospital admissions, or mortality for guiding appropriate therapy. According to GOLD 2013,[@b7-copd-11-697] patients with COPD can be classified into four severity categories: GOLD A (low risk, low symptoms), GOLD B (low risk, more symptoms), GOLD C (high risk, low symptoms), and GOLD D (high risk, more symptoms). More recent updates of the GOLD strategy maintained the same treatment paradigm.

Given the burden of COPD encompasses acute exacerbations requiring hospitalization, it is important to assess the epidemiology and rates of COPD exacerbations and resource use across settings of care. The objectives of this study were to assess the demographic and clinical characteristics of patients with COPD, including prescribed medications; quantify the rates of exacerbations in the COPD population in the UK; and assess the resource utilization in both primary and secondary care according to the latest available at the time -- GOLD 2013 severity categories.

Methods
=======

Data
----

The diagnosis and management of COPD in the UK is performed mainly by GPs in the primary care setting; however, the occurrence of acute exacerbations often necessitates hospital treatment. For this reason, data from both the primary and secondary care settings were extracted from the Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics (HES). In 2015, the CPRD covered \~8.5% of the UK population, including practices in England, Northern Ireland, Scotland, and Wales, with 13.1 million research quality acceptable patient records included in the database, known to be broadly representative of the demographic breakdown of the UK population.[@b8-copd-11-697] For this study, only the subset of patients in CPRD who could be linked to HES (\~58% of the practices) was used. HES contains information on admissions to National Health Service hospitals in England, including records from all admitted patients in acute hospitals, primary care trusts, and mental health trusts. Study protocol approval was given by the Independent Scientific Advisory Committee of the Medicines and Healthcare products Regulatory Agency Database Research (protocol number 15_006R). The data used in this study were non-identifiable, therefore patients' informed consent was not required as part of the protocol approval process.

Study population
----------------

Patients registered in a CPRD practice that could be linked to HES with a diagnosis of COPD identified through Read codes anytime in their medical record up to January 1, 2011 were extracted ([Table S1](#SD1-copd-11-697){ref-type="supplementary-material"}). The validity of using Read codes to identify patients with COPD in the CPRD has been demonstrated in a recent study.[@b9-copd-11-697] Patients were included if they were 40 years old and above at the time of diagnosis, if they were active on January 1, 2011, and had a minimum of 12 months of active data prior to cohort entry. Patients were followed-up longitudinally until the earliest of: patient death, transfer out of the GP practice, or end of the study period (December 31, 2013).

At cohort entry, the study population was stratified by severity of COPD based on the classification system in the GOLD 2013 management strategy.[@b7-copd-11-697] Records of spirometry and dyspnea measurements available in CPRD and exacerbations in the 12 months prior to January 1, 2011 were used. More detail on the parameters required for the severity classification is provided in our previous research.[@b4-copd-11-697]

Study measures
--------------

### Baseline characteristics

Patient demographic and clinical characteristics, including age, sex, smoking history, body mass index, and frequent comorbid conditions reported in previous literature,[@b10-copd-11-697] were described on January 1, 2011 (index date) using data from the 12 months prior (baseline period) as necessary; chronic comorbid conditions were assessed using all available records. Age at time of first COPD diagnosis code recorded also was described. COPD maintenance medication was investigated through prescriptions recorded in primary care during the 6 months prior to index date. Medications of interest included monotherapies and combination treatments as recommended by GOLD[@b7-copd-11-697]: reliever medications (short-acting beta agonists, short-acting anticholinergics), medications for maintained symptom relief (long-acting beta agonists, long-acting anticholinergics, inhaled corticosteroids), methylxanthines, and oral corticosteroids (OCS) excluding those prescribed during an exacerbation episode.

Outcomes
--------

The main outcomes in this study were the rate of COPD exacerbations and use of primary and secondary health care resources from index date until end of December 2013.

### Exacerbations

COPD exacerbations were captured using information from both primary and secondary care records, and episodes identified in both settings occurring within a 21-day time period were considered a single episode. In primary care, exacerbations were identified as: A Read code in the clinical record indicating exacerbations or emergency admission to hospital due to COPD ([Table S2](#SD2-copd-11-697){ref-type="supplementary-material"}); orAn OCS and oral antibiotic prescription occurring on the same date with the OCS not being used as maintenance treatment; orAn OCS or oral antibiotic prescription that is not part of a maintenance episode occurring on the same date as a specific list of Read codes indicating exacerbations.

In secondary care, an exacerbation was defined as a hospitalization in HES with the International Statistical Classification of Diseases and Related Health Problems; 10th Revision (ICD-10) code J44.1 "Chronic obstructive pulmonary disease with acute exacerbation, unspecified" within the reasons for admission.

### Resource use

Health care resources in primary care included GP visits (at the surgery, home, and telephone consultations). Hospitalizations were captured in HES and defined as COPD-related if they had at least one COPD ICD-10 code within the reasons for admission ([Table S3](#SD3-copd-11-697){ref-type="supplementary-material"}).

Statistical analyses
--------------------

All analyses were reported for the overall COPD study cohort and by GOLD 2013 severity category. Patient characteristics, including parameters for GOLD classification, were described using number and percentage of patients for categorical variables, and mean (standard deviation) for continuous variables. COPD maintenance medication use was presented using number and percentage of patients who received at least one prescription of that medication group.

Incidence rates of COPD exacerbations (per person-year) and confidence intervals (CIs) were calculated by dividing the number of episodes during the total follow-up by the number of person-years at risk among the overall COPD cohort over the same period. Annual incidence rates of exacerbations, hospitalizations, and GP visits were calculated using the same method for years 2011--2013. Multiple events per patient were accounted for by fitting frailty Poisson models to estimate the variance-corrected CIs around the incidence rates.

Statistical analysis was performed using SAS software version 9.4 and STATA software version 11.

Results
=======

Study sample
------------

Overall, 151,203 patients with a Read code indicative of COPD anytime in their medical record prior to January 1, 2011 were identified. Of these, 72,615 patients (48.%) had their first COPD record at 40 years or older, were active on January 1, 2011, and had 12 months of data history. The subset of 44,201 (61%) patients registered in a GP practice linked to HES constituted the study cohort.

The study cohort was further stratified by severity at index date based on the GOLD 2013 classification. Of patients with valid forced expiratory volume in 1 second measurements (74.5%), the majority presented with mild-to-moderate airflow limitation (70.0%), while 30.0% had severe or very severe airflow limitation placing them into the high-risk category ([Table 1](#t1-copd-11-697){ref-type="table"}). The modified Medical Research Council (mMRC) scores for dyspnea assessment were recorded in 83.5% of patients with COPD. More than half of them had an assessment of Grade 0--1 dyspnea (51.9%) versus 48.1% with Grade 2 and higher. At least one exacerbation was recorded for 54.9% of patients in the 12 months prior to index date; 29.2% of patients presented with two or more exacerbations.

On the basis of available mMRC scores and history of exacerbations, 83.5% of the overall COPD cohort were classified into the GOLD 2013 severity categories: GOLD A: 28.3%, GOLD B: 17.5%, GOLD C:15.1%, and GOLD D: 22.6%. Due to incomplete recording of mMRC measurements, 16.5% of patients remained unclassified.

Baseline characteristics
------------------------

For the overall cohort, the mean (standard deviation) age at COPD diagnosis was 66.3 years (10.6), 52.0% were male, and the mean time from diagnosis to index date (January 1, 2011) was 4.7 years. The most frequently recorded comorbidities were hypertension (35.4%), diabetes (16.9%), and osteoporosis (9.4%). Overall, 27.3% of patients were current smokers and 53.8% were former smokers, with a mean body mass index of 27 kg/m^2^ ([Table 2](#t2-copd-11-697){ref-type="table"}).

Baseline characteristics of patients with COPD by severity category are shown in [Table 2](#t2-copd-11-697){ref-type="table"}. The mean (standard deviation) age at index ranged from 69.8 years (9.9) for patients in the GOLD C category to 73.9 years (10.6) in patients classified as GOLD B. The distribution of comorbidities was similar across severity groups with the most frequently reported conditions being hypertension (GOLD A: 34.4%, GOLD B: 39.3%, GOLD C: 34.5%, and GOLD D: 34.7%), followed by diabetes (GOLD A: 14.4%, GOLD B: 19.9%, GOLD C: 14.5%, and GOLD D: 18.9%) and osteoporosis (GOLD A: 6.9%, GOLD B: 10.5%, GOLD C: 7.7%, and GOLD D: 12.4%). The highest proportion of patients with a smoking history was recorded in the GOLD D category, with 86.6% of patients classified as current or former smokers (current: 28.3%, former: 58.3%). The use of reliever monotherapy was highest among patients in GOLD A, with 15.8% of them on short-acting beta agonists, and the highest proportion on controller monotherapy for maintained relief was among patients in the GOLD C category, with 12.1% on long-acting beta agonists. The majority of patients in the most severe GOLD D category were on a combination therapy (74.6%), with the most frequently prescribed combination being long-acting beta agonists + long-acting anticholinergics + inhaled corticosteroids (29.9%). A total of 22.8% of patients in the GOLD A category were not on any maintenance medication in the 6 months prior to index date, whereas the proportion of patients not on any treatment in the GOLD D category was low, at 3.7%.

Patients who could not be classified into GOLD severity categories had a mean age of 71.4 years at January 1, 2011; 53.4% were females, with a mean body mass index of 27 and 74.5% were current or former smokers. A high proportion (36.8%) had not been prescribed any medication at the time of COPD severity assessment, but no significant differences in the frequency distribution of comorbidities were observed when compared to GOLD classified patients (data not shown).

Rate of COPD exacerbations
--------------------------

The rate of COPD exacerbations among the overall COPD cohort was 1.43 exacerbations per person-year (95% CI: 1.42--1.45) ([Table 3](#t3-copd-11-697){ref-type="table"}). Exacerbations increased by severity of COPD, ranging from 0.83 (95% CI: 0.81--0.85) exacerbations per person-year in GOLD A category to 2.51 (95% CI: 2.47--2.55) in GOLD D category. The rate of exacerbations among unclassified patients during the observation period was lower than classified patients (1.0 exacerbation per person-year).

During the study period, the annual rates of exacerbations showed a statistically significant year over year increase from 2011 to 2013 ([Figure 1](#f1-copd-11-697){ref-type="fig"}) across all GOLD categories. The annual rates of exacerbations increased from 0.69 (95% CI: 0.67--0.71), 1.01 (95% CI: 0.98--1.04), 1.65 (95% CI: 1.61--1.70), and 2.39 (95% CI: 2.35--2.44) per person-year for categories GOLD A, B, C, and D, respectively, in 2011 to 0.97 (95% CI: 0.94--1.00), 1.33 (95% CI: 1.28--1.38), 1.88 (95% CI: 1.83--1.94), and 2.61 (95% CI: 2.55--2.67) exacerbations per person-year in 2013.

Resource use
------------

The 2011 rates of GP visits were found to increase with disease severity ranging from 4.82 (94% CI: 4.74--4.93) GP visits per person-year in GOLD A to 7.44 (95% CI: 7.31--7.61) in GOLD D. During the study period, the annual rates of GP visits remained stable among patients in the lower severity categories, whereas a decreasing trend was observed in the higher severity categories. The greatest decrease was observed in patients classified as GOLD D, from 7.44 (95% CI: 7.31--7.61) GP visits per person-year in 2011 to 6.91 (95% CI: 6.75--7.10) in 2013.

COPD-related admissions for the overall follow-up were higher among patients with more symptoms (GOLD B: 0.52, GOLD D: 0.84) compared to patients with less symptoms (GOLD A: 0.28, GOLD C: 0.39). During the study period, the annual rates of COPD-related hospitalizations increased from 2011 to 2013 irrespective of severity of COPD ([Table 4](#t4-copd-11-697){ref-type="table"}). For patients in GOLD A and B, COPD-related hospitalizations significantly increased within 2 years from 0.22 (95% CI: 0.20--0.25) and 0.48 (95% CI: 0.46--0.51) admissions per person-year in 2011 to 0.34 (95% CI: 0.31--0.40) and 0.57 (95% CI: 0.54--0.61) in 2013, respectively. The year over year increase (2011--2012 and 2012--2013) was not statistically significant. Similarly, upward trends in COPD-related rates of hospitalizations were observed for categories GOLD C and D, from 0.36 (95% CI: 0.33--0.40) and 0.79 (95% CI: 0.75--0.84), in 2011 to 0.44 (95% CI: 0.40--0.48) and 0.85 (95% CI: 0.81--0.89) in 2013; however, the increase within the two study years was not statistically significant.

No clear pattern was observed in annual non-COPD hospitalization rates among GOLD A, B, C, and D severity categories. A slight decrease over time in the annual rates of non-COPD hospitalizations was seen in categories C and D, from 0.36 and 0.49 per person-year in 2011 to 0.32 and 0.28 in 2013, respectively ([Table 4](#t4-copd-11-697){ref-type="table"}).

Discussion
==========

To our knowledge, this is the first study to report exacerbation rates captured in both primary and secondary care by disease severity as outlined in the GOLD 2013 management strategy in the UK.[@b7-copd-11-697] The rates of exacerbations differed between the GOLD categories and showed a large upward trend with increasing level of disease severity from GOLD A (0.83 exacerbations per person-year, 95% CI: 0.81--0.85) to GOLD D (2.51 exacerbations per person-year, 95% CI: 2.47--2.55) categories. Our study revealed a year over year increase in the annual rate of exacerbations from 2011 to 2013 across all levels of severity. Using a smaller sample of patients with COPD, prior research in UK primary care assessed the frequency of exacerbations according to mild--moderate, severe, and very severe COPD categories using forced expiratory volume in 1 second measurements as outlined in the 2004 National Institute for Health and Clinical Excellence guidance.[@b1-copd-11-697],[@b11-copd-11-697] The mean annual exacerbation frequency increased from 1.1 in patients with mild--moderate COPD to 2.2 in very severe COPD. Previously published research investigating risk factors for acute exacerbations showed that history of exacerbations is most strongly associated with moderate-to-severe exacerbation frequency.[@b12-copd-11-697] The frequency of exacerbations has been shown[@b13-copd-11-697] to contribute to disease progression. Long-term data from previous research[@b14-copd-11-697] investigating the natural history of the disease suggested a rapid decline in health status after the second severe exacerbation and high mortality following every severe exacerbation requiring hospitalization.

The National Health Service Quality and Outcomes Framework,[@b15-copd-11-697],[@b16-copd-11-697] an annual reward and incentive program detailing GP practice achievement results, includes indicators for COPD from initial diagnosis to ongoing management. Our findings confirm that patients with COPD are mainly managed by primary care physicians. The annual rates of GP visits were shown to increase with disease severity from 4.8 GP visits per person-year in GOLD A category to 7.4 GP visits per person-year in GOLD D category, in 2011. However, throughout the observation period, GP visits showed a decreasing trend among higher severity categories. Given the progressive nature of the disease,[@b7-copd-11-697] these results could indicate a shift from the primary to secondary care setting as patients in more severe categories need more specialist support or get hospitalized. The high economic impact of COPD on health care systems has been demonstrated previously[@b17-copd-11-697] with more than 50% of COPD direct costs in the UK resulting from inpatient admissions. In our study, the annual rates of COPD-related hospital admissions were highest among patients with higher disease symptoms categorized as GOLD B (2011: 0.5 per person-year) and GOLD D (2011: 0.8 per person-year). In 2013, these rates increased to 0.6 and 0.9 admissions per person-year, respectively. In this descriptive study, no assessment on the risk factors for hospital admission was performed that can explain what the drivers of higher hospital admissions in categories with more symptoms are. A recent study found that history of exacerbation of COPD requiring hospital admission was associated with the highest risk of a new hospitalization for exacerbation,[@b18-copd-11-697] whereas a previous systematic literature review[@b19-copd-11-697] found both dyspnea symptoms and previous admissions to be significant factors for readmission. Between GOLD B and C categories, higher rates of COPD-related admissions in the first group indicate that although patients in GOLD B incur fewer exacerbations compared to GOLD C, these are likely to be more severe and lead to hospital admission. On the other hand, patients in GOLD C category have a higher frequency of exacerbations, but these are likely milder episodes that are managed in primary care, in line with our findings that GOLD C patients have higher rates of GP visits compared to GOLD B (2011: 5.91 versus 6.30 visits per person-year). Annual rates for non-COPD hospitalizations did not follow a clear pattern among patients in GOLD A, B, C, and D severity categories, suggesting that COPD symptoms constituted the major differential factor in secondary care resource use across GOLD categories. The prevalence of comorbidities was found to be high among all patients with COPD; however, a similar prevalence distribution across severity categories was observed, with the most common conditions being hypertension, diabetes, and osteoporosis. Our findings were in line with the most common comorbidities associated with COPD reported in previous studies, although precise prevalence numbers differ due to the variation in methodological approaches.[@b10-copd-11-697],[@b20-copd-11-697] Annual rates of non-COPD admissions among newly-diagnosed patients with COPD captured from primary care records were estimated in previous research to be between 0.4 and 0.5 admissions per patient per year for patients with mild to very severe COPD,[@b3-copd-11-697] corroborating the findings from our study.

The major strengths of our study include the use of a large database representative of the UK population and inclusion of secondary care data from HES. Given the recording of exacerbations is not standardized in CPRD, necessitating the use of algorithms to identify these events,[@b3-copd-11-697],[@b4-copd-11-697],[@b21-copd-11-697]--[@b23-copd-11-697] our study improved existing methodology by using a holistic definition combining prescriptions and diagnosis records in primary care with records of hospital admission in the secondary care setting. Records of COPD-related admissions indicating an exacerbation in CPRD were validated by comparing these with data in HES. After investigation of the episodes identified, our conclusion was that exacerbations are generally well reported in primary care with the results being consistent using records from both settings.

A limitation of the study was the missing mMRC records for dyspnea assessment that did not allow the classification of all patients into GOLD categories. Nevertheless, only 17% of patients remained unclassified. A lower rate of exacerbations among unclassified patients (1.0 exacerbation per person-year), and a high proportion (36.8%) with any medication prescribed at the time of COPD severity assessment pointed at these patients being less severe; however, this finding might also indicate that their COPD is less monitored and subsequently treated inadequately. An additional study limitation was that patients were not further reclassified by GOLD criteria which may impact results, especially at later time points. Still, based on estimates of disease progression, it is unlikely that many patients will have transitioned between GOLD categories over the course of this study.[@b24-copd-11-697],[@b25-copd-11-697]

Length of stay of hospitalizations and data on the severity of exacerbation, such as respiratory failure, high dependency admission, or mortality among hospitalized patients by COPD severity, could not be assessed due to limitations in data availability. Existing evidence from Thomas et al[@b11-copd-11-697] in ten GP practices in the UK showed that the median length of hospital stay for COPD-related admissions was similar between severity groups measured by spirometry (5 days in mild--moderate \[interquartile range: 2--10\] and severe COPD \[2--9\]; 6 days \[3--11\] in very severe COPD).

The design of our study precluded us from assessing the effect of different COPD maintenance treatments on exacerbation rates, hospital admissions, and exacerbation severity. Of note, existing evidence on comparative treatment efficacy has shown that combination treatments lead to a reduction in exacerbation rates compared to monotherapies or inhaled corticosteroids alone; however, no clear evidence exists using hospital admissions and severity of exacerbation endpoints.[@b26-copd-11-697],[@b27-copd-11-697] Evidence from real-world effectiveness studies is also sparse. Kozma et al[@b28-copd-11-697] found no significant differences in hospital admissions among different inhaled therapies with long-acting bronchodilators. Others showed that in comparison to nonusers, maintenance therapy was associated with significantly lower risk of hospitalization and rehospitalization; however, no comparison on the magnitude of the effect between different treatments was performed.[@b29-copd-11-697] Given limited evidence exists to date, the authors believe this is an interesting area to focus in future research.

Conclusion
==========

Patients in the most severe category (GOLD D) experienced nearly three times the number of exacerbations and COPD-related hospital admissions as those in the least severe category (GOLD A). In addition to a year over year increase in exacerbations over the study period, GP visits were found to increase substantially with disease severity; however, for higher severity categories, GP visits decreased over time. These findings suggest a possible shift of patient care from primary to secondary care driven by the progressive severity of the disease. Our findings suggest that management of COPD in earlier stages to stabilize disease progression could be beneficial for reducing exacerbation frequency and health care resource utilization.

Supplementary materials
=======================

###### 

Read codes for COPD

  Read code   Read term
  ----------- ---------------------------------------------------------------
  661M300     COPD self-management plan agreed
  661N300     COPD self-management plan review
  66YB.00     Chronic obstructive pulmonary disease monitoring
  66YB000     Chronic obstructive pulmonary disease 3 monthly review
  66YB100     Chronic obstructive pulmonary disease 6 monthly review
  66Yd.00     COPD accident and emergency attendance since last visit
  66YD.00     Chronic obstructive pulmonary disease monitoring due
  66Ye.00     Emergency COPD admission since last appointment
  66Yf.00     Number of COPD exacerbations in past year
  66Yg.00     Chronic obstructive pulmonary disease disturbs sleep
  66Yh.00     Chronic obstructive pulmonary disease does not disturb sleep
  66YI.00     COPD self-management plan given
  66Yi.00     Multiple COPD emergency hospital admissions
  66YL.00     Chronic obstructive pulmonary disease follow-up
  66YL.11     COPD follow-up
  66YL.12     COAD follow-up
  66YM.00     Chronic obstructive pulmonary disease annual review
  66YS.00     Chronic obstructive pulmonary disease monitoring by nurse
  66YT.00     Chronic obstructive pulmonary disease monitoring by doctor
  8BMa000     Chronic obstructive pulmonary disease medication optimisation
  8BMW.00     Issue of chronic obstructive pulmonary disease rescue pack
  8CMV.00     Has chronic obstructive pulmonary disease care plan
  8CMW500     Chronic obstructive pulmonary disease care pathway
  8CR1.00     Chronic obstructive pulmonary disease clini management plan
  8H2R.00     Admit COPD emergency
  9e03.00     GP OOH service notified of COPD care plan
  9kf0.00     COPD patient unsuitable for pulmonary rehab -- enh serv admin
  9kf0.11     COPD patient unsuitable for pulmonary rehabilitation
  9NgP.00     On chronic obstructive pulmonary disease supprtv cre pathway
  9NgP.11     On COPD (chr obstruc pulmonary disease) supportv cre pathway
  9Oi..00     Chronic obstructive pulmonary disease monitoring admin
  9Oi0.00     Chronic obstructive pulmonary disease monitoring 1st letter
  9Oi1.00     Chronic obstructive pulmonary disease monitoring 2nd letter
  9Oi2.00     Chronic obstructive pulmonary disease monitoring 3rd letter
  9Oi3.00     Chronic obstructive pulmonary disease monitoring verb invite
  9Oi4.00     Chronic obstructive pulmonary disease monitor phone invite
  H3...00     Chronic obstructive pulmonary disease
  H3...11     Chronic obstructive airways disease
  H31..00     Chronic bronchitis
  H310.00     Simple chronic bronchitis
  H310000     Chronic catarrhal bronchitis
  H310z00     Simple chronic bronchitis NOS
  H311.00     Mucopurulent chronic bronchitis
  H311000     Purulent chronic bronchitis
  H311100     Fetid chronic bronchitis
  H311z00     Mucopurulent chronic bronchitis NOS
  H312.00     Obstructive chronic bronchitis
  H312000     Chronic asthmatic bronchitis
  H312011     Chronic wheezy bronchitis
  H312100     Emphysematous bronchitis
  H312200     Acute exacerbation of chronic obstructive airways disease
  H312z00     Obstructive chronic bronchitis NOS
  H313.00     Mixed simple and mucopurulent chronic bronchitis
  H31y.00     Other chronic bronchitis
  H31yz00     Other chronic bronchitis NOS
  H31z.00     Chronic bronchitis NOS
  H32..00     Emphysema
  H320.00     Chronic bullous emphysema
  H320000     Segmental bullous emphysema
  H320100     Zonal bullous emphysema
  H320200     Giant bullous emphysema
  H320300     Bullous emphysema with collapse
  H320z00     Chronic bullous emphysema NOS
  H321.00     Panlobular emphysema
  H322.00     Centrilobular emphysema
  H32y.00     Other emphysema
  H32y200     MacLeod's unilateral emphysema
  H32yz00     Other emphysema NOS
  H32z.00     Emphysema NOS
  H36..00     Mild chronic obstructive pulmonary disease
  H37..00     Moderate chronic obstructive pulmonary disease
  H38..00     Severe chronic obstructive pulmonary disease
  H39..00     Very severe chronic obstructive pulmonary disease
  H3A..00     End stage chronic obstructive airways disease
  H3y..00     Other specified chronic obstructive airways disease
  H3y..11     Other specified chronic obstructive pulmonary disease
  H3z..00     Chronic obstructive airways disease NOS
  H3z..11     Chronic obstructive pulmonary disease NOS
  H581.00     Interstitial emphysema
  H582.00     Compensatory emphysema
  Hyu3000     \[X\]Other emphysema
  Q312111     Perinatal mediastinal emphysema
  SK07.00     Subcutaneous emphysema

**Notes:** "\[X\]" indicates cross referenced to specific ICD-10 codes. Data from the CPRD database (terms and wording are unedited, to match the original source).

**Abbreviations:** admin, administration; chr obstruct, chronic obstructive; clini, clinical; COAD, chronic obstructive airways disease; COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice Research Datalink; enh serv admin, enhanced services administration; GP, general practitioner; ICD-10, International Statistical Classification of Diseases and Related Health Problems; 10th Revision; NOS, not otherwise specified; OOH, out of office hours; rehab, rehabilitation; verb, verbal.

###### 

Read codes for exacerbations

  Medical code   Read code   Read term
  -------------- ----------- -------------------------------------------------------------
  1446           H312200     Acute exacerbation of chronic obstructive airways disease
  7884           H3y1.00     Chron obstruct pulmonary dis wth acute exacerbation, unspec
  100123         8BP8.00     Antibiotic therapy for acute pulmonary exacerbation
  11019          8H2R.00     Admit COPD emergency
  19003          66Ye.00     Emergency COPD admission since last appointment
  19106          66Yd.00     COPD accident and emergency attendance since last visit
  46036          66Yi.00     Multiple COPD emergency hospital admissions

**Notes:** Data from the CPRD database (terms and wording are unedited, to match the original source).

**Abbreviations:** chron, chronic; COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice Research Datalink; dis, disease; obstruct, obstructive; unspec, unspecified; wth, with.

###### 

ICD-10 codes for COPD-related hospitalization

  ICD-10 code   Description
  ------------- ------------------------------------------------------------------------------
  J40           Bronchitis, not specified as acute or chronic
                Incl:
                 Bronchitis:
                  NOS
                  Catarrhal
                  With tracheitis NOS
                 Tracheobronchitis NOS
  J41           Simple and mucopurulent chronic bronchitis
  J41.0         Simple chronic bronchitis
  J41.1         Mucopurulent chronic bronchitis
  J41.8         Mixed simple and mucopurulent chronic bronchitis
  J42           Unspecified chronic bronchitis
                Incl:
                 Chronic:
                  Bronchitis NOS
                  Tracheitis
                  Tracheobronchitis
  J43           Emphysema
  J43.0         MacLeod syndrome
                 Unilateral:
                  Emphysema
                  Transparency of lung
  J43.1         Panlobular emphysema
                 Panacinar emphysema
  J43.2         Centrilobular emphysema
  J43.8         Other emphysema
  J43.9         Emphysema, unspecified
                 Emphysema (lung) (pulmonary):
                  NOS
                  Bullous
                  Vesicular
                Emphysematous bleb
  J44           Other chronic obstructive pulmonary disease
                Incl:
                 Chronic:
                  Bronchitis:
                   Asthmatic (obstructive)
                   Emphysematous
                   With:
                    Airways obstruction
                    Emphysema
                  Obstructive:
                   Asthma
                   Bronchitis
                   Tracheobronchitis
  J44.0         Chronic obstructive pulmonary disease with acute lower respiratory infection
  J44.1         Chronic obstructive pulmonary disease with acute exacerbation, unspecified
  J44.8         Other specified chronic obstructive pulmonary disease
                Chronic bronchitis:
                  Asthmatic (obstructive) NOS
                  Emphysematous NOS
                  Obstructive NOS
  J44.9         Chronic obstructive pulmonary disease, unspecified chronic obstructive:
                  Airway disease NOS
                  Lung disease NOS
  J47           Bronchiectasis
                Incl:
                 Bronchiolectasis
  J80           Adult respiratory distress syndrome
                Incl:
                 Adult hyaline membrane disease

**Notes:** Data from the World Health Organization (terms and wording are unedited, to match the original source).[@b30-copd-11-697]

**Abbreviations:** COPD, chronic obstructive pulmonary disease; ICD-10, International Statistical Classification of Diseases and Related Health Problems; 10th Revision; incl, including; NOS, not otherwise specified.

**Disclosure**

This analysis was sponsored by Takeda Pharmaceuticals International, Inc. Evie Merinopoulou, Mireia Raluy-Callado, Sreeram Ramagopalan, and Sharon MacLachlan are full-time employees of Evidera and served as paid consultants to Takeda Pharmaceuticals International Inc. for conducting this study. Javaria Mona Khalid is a full-time employee of Takeda Development Centre Europe Ltd. The authors report no other conflicts of interest in this work.

![Annual rates of exacerbations at follow-up (per person-year).\
**Abbreviation:** GOLD, Global Initiative for Chronic Obstructive Lung Disease.](copd-11-697Fig1){#f1-copd-11-697}

###### 

GOLD classification parameters at index

                                                     Overall COPD cohort (N=44,201), n (%)
  -------------------------------------------------- ---------------------------------------
  FEV~1~ (at least one test recorded)                32,908 (74.5)
   Mild: FEV~1~ ≥80% predicted                       5,628 (18.7)
   Moderate: 50% ≤ FEV~1~ \<80% predicted            15,427 (51.3)
   Severe: 30% ≤ FEV~1~ \<50% predicted              7,387 (24.6)
   Very severe: FEV~1~ \<30% predicted               1,634 (5.4)
  mMRC Dyspnea Scale (at least one score recorded)   36,914 (83.5)
   Grade 0                                           6,105 (16.5)
   Grade 1                                           13,077 (35.4)
   Grade 2                                           9,596 (26.0)
   Grade 3                                           6,418 (17.4)
   Grade 4                                           1,718 (4.7)
  Number of exacerbations                            
   0                                                 19,948 (45.1)
   1                                                 11,371 (25.7)
   2+                                                12,882 (29.2)

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council.

###### 

Baseline characteristics of the overall COPD cohort and by GOLD category

                                                       GOLD A (N=12,493)   GOLD B (N=7,752)   GOLD C (N=6,689)   GOLD D (N=9,980)   Overall COPD cohort (N=44,201)
  ---------------------------------------------------- ------------------- ------------------ ------------------ ------------------ --------------------------------
  Age at index (January 1, 2011), mean (SD)            69.9 (10.4)         73.9 (10.6)        69.8 (9.9)         72.6 (9.9)         71.5 (10.7)
  Sex, n (%)                                                                                                                        
   Male                                                6,802 (54.0)        3,810 (49.0)       3,645 (54.0)       5,297 (53.0)       22,953 (52.0)
   Female                                              5,691 (46.0)        3,942 (51.0)       3,044 (46.0)       4,683 (47.0)       21,248 (48.0)
  Age at diagnosis, mean (SD)                          65.3 (10.2)         68.6 (10.7)        64.8 (9.8)         66.6 (10.0)        66.3 (10.6)
  Time since diagnosis (months), mean (SD)             49.2 (38.9)         58.2 (43.9)        54.0 (42.3)        67.4 (47.4)        56.3 (43.2)
  Comorbidities, n (%)                                                                                                              
   Myocardial infarction                               854 (6.8)           814 (10.5)         471 (7.0)          1,020 (10.2)       3,797 (8.6)
   Diabetes                                            1,805 (14.4)        1,546 (19.9)       971 (14.5)         1,883 (18.9)       7,455 (16.9)
   Hypertension                                        4,292 (34.4)        3,046 (39.3)       2,308 (34.5)       3,464 (34.7)       15,647 (35.4)
   Osteoporosis                                        868 (6.9)           813 (10.5)         517 (7.7)          1,235 (12.4)       4,162 (9.4)
   Anxiety                                             215 (1.7)           108 (1.4)          126 (1.9)          225 (2.3)          811 (1.8)
   Depression                                          294 (2.4)           205 (2.6)          176 (2.6)          326 (3.3)          1,197 (2.7)
  Smoking history, n (%)                                                                                                            
   Unknown                                             1,407 (11.3)        1,001 (12.9)       461 (6.9)          727 (7.3)          4,313 (9.8)
   Current smoker                                      3,331 (26.7)        1,904 (24.6)       2,079 (31.1)       2,824 (28.3)       12,073 (27.3)
   Never smoked                                        1,136 (9.1)         617 (8.0)          533 (8.0)          608 (6.1)          4,035 (9.1)
   Ex-smoker                                           6,619 (53.0)        4,230 (54.6)       3,616 (54.1)       5,821 (58.3)       23,780 (53.8)
  BMI (kg/m^2^), mean (SD)                             27 (5.4)            28.1 (6.9)         26.4 (5.5)         26.7 (6.8)         27 (6.2)
  Maintenance therapy, n (%)                                                                                                        
   Monotherapy                                         5,093 (40.8)        2,684 (34.6)       2,390 (35.7)       2,158 (21.6)       14,538 (32.9)
   Combination therapy                                 4,531 (36.3)        4,209 (54.3)       3,675 (54.9)       7,444 (74.6)       22,217 (50.3)
   Patients not on any treatment                       2,845 (22.8)        846 (10.9)         614 (9.2)          372 (3.7)          7,358 (16.6)
  Total monotherapies, n (%)                           5,093 (40.8)        2,684 (34.6)       2,390 (35.7)       2,158 (21.6)       14,538 (32.9)
   SABA                                                1,968 (15.8)        816 (10.5)         780 (11.7)         490 (4.9)          5,079 (11.5)
   SAMA                                                228 (1.8)           93 (1.2)           81 (1.2)           61 (0.6)           528 (1.2)
   LABA                                                1,423 (11.4)        869 (11.2)         808 (12.1)         867 (8.7)          4,625 (10.5)
   LAMA                                                1,224 (9.8)         822 (10.6)         641 (9.6)          690 (6.9)          3,676 (8.3)
    LAMA + SABA                                        754 (61.6)          594 (72.3)         485 (75.7)         561 (81.3)         2,595 (70.6)
    LAMA + SAMA                                        48 (3.9)            37 (4.5)           33 (5.1)           51 (7.4)           177 (4.8)
   Methylxanthines                                     10 (0.1)            6 (0.1)            3 (0.0)            4 (0.0)            33 (0.1)
   ICS                                                 240 (1.9)           78 (1.0)           77 (1.2)           46 (0.5)           597 (1.4)
   OCS                                                 24 (0.2)            13 (0.2)           10 (0.1)           6 (0.1)            88 (0.2)
  Total combination therapies, n (%)                   453 (36.3)          4,209 (54.3)       3,675 (54.9)       7,444 (74.6)       22,217 (50.3)
   LABA + ICS (as both FDC and combination)            1,884 (15.1)        1,131 (14.6)       1,141 (17.1)       1,321 (13.2)       6,486 (14.7)
    LABA + ICS + SABA                                  1,262 (67.0)        888 (78.5)         876 (76.8)         1,139 (86.2)       4,892 (75.4)
    LABA + ICS + SAMA                                  241 (12.8)          288 (25.5)         234 (20.5)         452 (34.2)         1,368 (21.1)
   LABA + LAMA + ICS                                   1,251 (10.0)        1,451 (18.7)       1,300 (19.4)       2,989 (29.9)       7,537 (17.1)
    LABA + LAMA + ICS + SABA                           926 (74.0)          1,217 (83.9)       1,103 (84.8)       2,719 (91.0)       6,426 (85.3)
    LABA + LAMA + ICS + SAMA                           46 (3.7)            60 (4.1)           88 (6.8)           231 (7.7)          470 (6.2)
   LAMA + ICS                                          59 (0.5)            39 (0.5)           35 (0.5)           49 (0.5)           197 (0.4)
    LAMA + ICS + SABA                                  34 (57.6)           28 (71.8)          29 (82.9)          40 (81.6)          143 (72.6)
    LAMA + ICS + SAMA                                  3 (5.1)             5 (12.8)           1 (2.9)            6 (12.2)           15 (7.6)
   LABA + LAMA                                         779 (6.2)           967 (12.5)         744 (11.1)         1,679 (16.8)       4,541 (10.3)
   SABA + SAMA only                                    368 (2.9)           278 (3.6)          199 (3.0)          208 (2.1)          1,195 (2.7)
   Methylxanthines + ICS                               47 (0.4)            63 (0.8)           44 (0.7)           143 (1.4)          360 (0.8)
   Methylxanthines + LABA                              36 (0.3)            42 (0.5)           34 (0.5)           98 (1.0)           251 (0.6)
   Methylxanthines + LAMA                              7 (0.1)             15 (0.2)           7 (0.1)            24 (0.2)           63 (0.1)
   Methylxanthines + (LABA or LAMA or ICS)             97 (0.8)            212 (2.7)          166 (2.5)          916 (9.2)          1,543 (3.5)
  Any other combinations, n (%)                        3 (0.0)             11 (0.1)           5 (0.1)            17 (0.2)           44 (0.1)
  Patients not on any of the above treatments, n (%)   2,845 (22.8)        846 (10.9)         614 (9.2)          372 (3.7)          7,358 (16.6)

**Abbreviations:** BMI, body mass index; COPD, chronic obstructive pulmonary disease; FDC, fixed-dose combination; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting anticholinergics; n, number of patients; OCS, oral corticosteroids; SABA, short-acting beta agonists; SAMA, short-acting anticholinergics; SD, standard deviation.

###### 

Rates of exacerbations during the follow-up period (per person-year) by GOLD category

  GOLD category   Total person-years at risk   Total number of exacerbations   Rate of exacerbations (per person-year)   95% CI lower   95% CI upper
  --------------- ---------------------------- ------------------------------- ----------------------------------------- -------------- --------------
  All patients    106,382.69                   152,403                         1.43                                      1.42           1.45
  GOLD A          31,967.67                    26,562                          0.83                                      0.81           0.85
  GOLD B          18,437.71                    21,480                          1.17                                      1.14           1.19
  GOLD C          16,638.72                    29,666                          1.78                                      1.74           1.82
  GOLD D          23,077.24                    57,893                          2.51                                      2.47           2.55

**Abbreviations:** CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

###### 

Annual resource use (per person-year) by GOLD category

  Year   GOLD category   Total person-years at risk   COPD-related hospitalizations   Non-COPD hospitalizations   GP visits
  ------ --------------- ---------------------------- ------------------------------- --------------------------- -------------------
  2011   GOLD A          11,893.16                    0.22 (0.20--0.25)               0.39 (0.38--0.40)           4.82 (4.74--4.93)
         GOLD B          7,195.80                     0.48 (0.46--0.51)               0.45 (0.43--0.46)           5.91 (5.78--6.07)
         GOLD C          6,275.49                     0.36 (0.33--0.40)               0.36 (0.34--0.37)           6.30 (6.16--6.47)
         GOLD D          9,183.12                     0.79 (0.75--0.84)               0.49 (0.48--0.50)           7.44 (7.31--7.61)
  2012   GOLD A          10,877.59                    0.29 (0.25--0.33)               0.44 (0.43--0.45)           4.82 (4.73--4.93)
         GOLD B          6,224.29                     0.53 (0.50--0.56)               0.43 (0.42--0.45)           5.66 (5.52--5.83)
         GOLD C          5,659.35                     0.39 (0.36--0.42)               0.38 (0.36--0.39)           6.29 (6.14--6.48)
         GOLD D          7,796.55                     0.88 (0.83--0.94)               0.40 (0.38--0.41)           7.16 (7.03--7.34)
  2013   GOLD A          8,957.15                     0.35 (0.31--0.40)               0.39 (0.37--0.40)           4.72 (4.62--4.84)
         GOLD B          4,888.70                     0.57 (0.54--0.61)               0.42 (0.41--0.44)           5.71 (5.54--5.89)
         GOLD C          4,580.30                     0.44 (0.40--0.48)               0.32 (0.30--0.34)           6.09 (5.93--6.28)
         GOLD D          5,945.35                     0.85 (0.81--0.89)               0.28 (0.27--0.30)           6.91 (6.75--7.10)

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, general practitioner.
